These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33252394)

  • 1. A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib.
    Hosokawa Y; Oiwa H
    J Clin Rheumatol; 2021 Dec; 27(8S):S661-S662. PubMed ID: 33252394
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.
    Kato M; Ikeda K; Kageyama T; Kasuya T; Kumagai T; Furuya H; Furuta S; Tamachi T; Suto A; Suzuki K; Nakajima H
    J Clin Rheumatol; 2021 Dec; 27(8S):S574-S577. PubMed ID: 30614890
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.
    Takatani A; Koga T; Fujita Y; Fukui S; Endo Y; Shimizu T; Kawakami A
    Clin Immunol; 2020 Jun; 215():108451. PubMed ID: 32360518
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.
    Xue Y; Zhang J; Deng J; Kuang W; Wang J; Tan X; Li C; Li S; Li C
    Ann Rheum Dis; 2023 Nov; 82(11):1499-1501. PubMed ID: 37280048
    [No Abstract]   [Full Text] [Related]  

  • 5. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.
    Takanashi S; Kaneko Y; Takeuchi T
    Mod Rheumatol; 2022 Jan; 32(1):231-237. PubMed ID: 33769925
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.
    Luo M; Chen L; He H; He F
    Eur J Med Res; 2022 May; 27(1):68. PubMed ID: 35570320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
    Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
    Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
    Ohmura SI; Yamabe T; Naniwa T
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):76-81. PubMed ID: 32867615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis Presenting as Refractory Gingivitis at the First Clinical Manifestation.
    Kawakami E; Uchida T; Iwamoto N; Hara K; Egashira K; Kawakami A
    Intern Med; 2024 Jan; 63(1):131-134. PubMed ID: 37197957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of anti-MDA-5 positive dermatomyositis with rapidly progressive interstitial lung disease.
    Fenando A; Firn K; Louissa S; Hussain A
    BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32354766
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
    Mehta AA; Paul T; Cb M; Haridas N
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin-B Hemoperfusion as a Novel Treatment for Rapidly Progressive Interstitial Lung Disease in a Pediatric Patient Diagnosed With Anti-MDA5 Juvenile Dermatomyositis.
    Mrosak J; Banasiak K; Edelheit B; Lapin C; Tory H; Collins MS
    J Clin Rheumatol; 2021 Dec; 27(8S):S480-S484. PubMed ID: 31743264
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
    Ishikawa Y; Kasuya T; Fujiwara M; Kita Y
    Medicine (Baltimore); 2020 Sep; 99(37):e21943. PubMed ID: 32925726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature.
    Yamazaki S; Shimizu M; Yakabe A; Inage E; Jimbo K; Suzuki M; Miyaoka F; Kaneko S; Irabu H; Shimbo A; Ohtomo Y; Mori M; Morio T; Shimizu T
    Immunol Med; 2024 Jun; 47(2):110-117. PubMed ID: 38557269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
    De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E
    Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent Treatment With Rituximab and Plasma Exchange for Rapidly Progressive Interstitial Lung Disease Complicating Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis.
    Shimizu M; Inoue N; Takeda Y; Kidouchi K; Fujita N; Fujiki T; Takasaki A; Adachi Y; Wada T
    J Clin Rheumatol; 2021 Dec; 27(8S):S798-S799. PubMed ID: 35073639
    [No Abstract]   [Full Text] [Related]  

  • 20. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
    Chen Z; Wang X; Ye S
    N Engl J Med; 2019 Jul; 381(3):291-293. PubMed ID: 31314977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.